Adaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) in a research report issued on Tuesday. The firm set a "buy" rating on the biotechnology company's stock.

ADAP has been the subject of several other reports. Wells Fargo & Company lowered their price objective on Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a research note on Friday, March 21st. HC Wainwright lowered their price objective on shares of Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Scotiabank lowered their price target on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating for the company in a research note on Friday, March 21st. Jones Trading downgraded shares of Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 11th. Finally, Guggenheim reduced their price target on Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating on the stock in a research note on Wednesday, March 26th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $1.83.

Adaptimmune Therapeutics Stock Performance

ADAP stock traded up $0.01 during trading hours on Tuesday, hitting $0.27. 432,387 shares of the stock were exchanged, compared to its average volume of 1,760,455. Adaptimmune Therapeutics has a 12 month low of $0.20 and a 12 month high of $1.48. The firm has a market capitalization of $68.58 million, a P/E ratio of -1.21 and a beta of 2.84. The company has a 50-day simple moving average of $0.37 and a two-hundred day simple moving average of $0.57. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The biotechnology company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.09). The firm had revenue of $3.22 million for the quarter, compared to analyst estimates of $16.56 million. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. On average, analysts forecast that Adaptimmune Therapeutics will post -0.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Two Sigma Investments LP grew its stake in Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 19,146 shares in the last quarter. Virtu Financial LLC lifted its position in shares of Adaptimmune Therapeutics by 21.5% during the 4th quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock worth $66,000 after purchasing an additional 21,688 shares during the last quarter. Invesco Ltd. boosted its holdings in Adaptimmune Therapeutics by 82.0% in the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 28,526 shares in the last quarter. Rock Springs Capital Management LP lifted its holdings in shares of Adaptimmune Therapeutics by 2.4% in the 4th quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock valued at $1,338,000 after purchasing an additional 58,000 shares during the last quarter. Finally, Two Sigma Advisers LP raised its holdings in shares of Adaptimmune Therapeutics by 492.0% in the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock valued at $38,000 after buying an additional 58,787 shares during the last quarter. 31.37% of the stock is owned by institutional investors and hedge funds.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.